

Self-Procurement of COVID-19 Vaccines and the COVAX Facility

Kristina Lorenson & Ann Ottosen
UNICEF Supply Division

16 December 2020
eVPPEF 2020



A Pooled Tender has been issued jointly by UNICEF and PAHO to secure access to at least 2 billion doses of vaccine to be delivered by end 2021

Purpose

Gavi, as COVAX Facility Secretariat, establishes advance purchase commitments (APCs)

UNICEF and PAHO establish procurement and supply arrangements based on the APCs

UNICEF, as COVAX Procurement Coordinator, establishes key basic terms that COVAX self-financing self-procuring participants reference in their supply agreements with manufacturers

Objectives

1. Speed

Expedite access to Covid-19 vaccines by building on push and pull contracts (established by BMGF, CEPI and Gavi) for the COVAX participating economies

2. Volumes

ACT-A target is to secure at least 2bn doses by end 2021

3. Price

Drawing on the financing and de-risking provided by the push and pull contracts and the pooled COVAX volumes, COVAX targets to achieve the lowest price on the market

4. Balanced Portfolio

Balanced geographically diverse portfolio across multiple vaccine platforms

COVAX Facility Supply

The Facility aspires to secure access to a diversified portfolio of 10 or more vaccines representing different technology platforms, product profiles, and manufacturing locations

▶ Illustrative Portfolio

Vaccine Candidate	Estimated # doses by end of 2021 (millions)
AstraZeneca	300
Sanofi/GSK	200
SII (AZ and Novavax)	200
Candidate 4	300
Candidate 5	100
Candidate 6	500
Candidate 7	750
Candidate 8	150
Candidate 9	400
Candidate 10	200
Candidate 11	600
Candidate 12	300
TOTAL	4,000

for illustrative purposes




Source: The Peterborough Examiner, 1 Nov 2020.

The Facility assumes a 50% attrition rate of pipeline vaccine candidates

Process for COVAX Facility Procurement

Obligations of:
 COVAX Facility or manufacturer
Self-Procuring Country
 Inform Procurement Coordinator: ★



Time Sensitive Activities to Take Delivery of Allocated Doses for Self-Procuring Participants

- Agree with manufacturer on terms and conditions for Supply Arrangements/Purchase Orders leveraging terms outlined in the Summary Sheet
- Sign Indemnity and Liability Agreement with manufacturer
- Obtain National regulatory approval or document waiver
- Obtain import license
- Purchase vaccine through the Facility and finance all costs related to delivery and importation
- Insure vaccines during transport, at its discretion and in-line with chosen Incoterms

Questions to stimulate discussions

- Given the current pandemic, are there emergency provisions in legislation to waive requirements for regulatory approvals and/or rely on regulatory reviews by other NRAs/WHO?
- Is a tender required/mandatory, or will the country be able to place purchase order based on a Term Sheet?
- The COVAX Facility will provide model provisions for an Indemnity and Liability agreement to be entered into between country and manufacturers as a precondition for delivery – are responsible lead identified for review and signature?
- Has budget been confirmed for vaccine purchase, immunization supplies, cold chain expansion (if required) and shipment?
- Given the time sensitivity to place a purchase order with the manufacturer within e.g. 4 weeks, what do you expect would be the bottlenecks?
- Other key issues of concerns?



THANK YOU